公开(公告)号：USRE49700E1

公开(公告)日：2023-10-17

申请号：US17183286

申请日：2021-02-23

Applicant: Bristol-Myers Squibb Company

Inventor： Navnath Dnyanoba Yadav ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Prashantha Gunaga ,  Manoranjan Panda ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

CPC classification number: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

Abstract: Disclosed are compounds of Formula (I)




or a salt thereof,

wherein R1 is:





each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US10562887B2

公开(公告)日：2020-02-18

申请号：US16098978

申请日：2017-05-26

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Natesan Murugesan ,  Peter W. Glunz ,  Mandar Shrikrishna Bodas ,  Navnath Dnyanoba Yadav ,  Venu Alla

IPC: C07D403/10 ,  C07D401/10 ,  C07D403/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

公开(公告)号：US20190152956A1

公开(公告)日：2019-05-23

申请号：US16098978

申请日：2017-05-26

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Natesan Murugesan ,  Peter W. Glunz ,  Mandar Shrikrishna Bodas ,  Navnath Dnyanoba Yadav ,  Venu Alla

IPC: C07D403/10 ,  C07D403/14 ,  C07D401/10 ,  C07D487/04 ,  C07D471/04

CPC classification number: C07D403/10 ,  C07D401/10 ,  C07D403/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

公开(公告)号：US10123993B2

公开(公告)日：2018-11-13

申请号：US15541725

申请日：2016-01-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter W. Glunz ,  Doree F. Sitkoff ,  Navnath Dnyanoba Yadav ,  Mandar Shrikrishna Bodas ,  Rajeev S. Bhide ,  Sharanabasappa Patil ,  Kumaresan Chinnakotti ,  Prasanna Savanor Maddu Rao ,  Jeevan Prakash Shetty

IPC: A61K31/4178 ,  A61K31/422 ,  A61K31/498 ,  C07D401/14 ,  C07D401/10 ,  C07D403/10 ,  C07D413/10 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

公开(公告)号：US09238666B2

公开(公告)日：2016-01-19

申请号：US14406543

申请日：2013-06-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Jayakumar S. Warrier ,  Navnath Dnyanoba Yadav

IPC: C07F9/6512 ,  C07D401/14 ,  C07F9/6558 ,  A61K31/675

CPC classification number: C07F9/65128 ,  A61K31/675 ,  C07D401/14 ,  C07F9/65583

Abstract: A compound of structural formula (I), wherein R is H or —PO3H or a pharmaceutically acceptable salt form thereof. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.

Abstract translation: 结构式（I）的化合物，其中R是H或-PO 3 H或其药学上可接受的盐形式。 这些化合物可用作钾通道功能的抑制剂和治疗和预防心律失常，IKur相关疾病以及由离子通道功能介导的其它病症。

公开(公告)号：US20150175641A1

公开(公告)日：2015-06-25

申请号：US14406543

申请日：2013-06-10

Applicant: Bristol-Myers Squibb Company

Inventor： Jayakumar S. Warrier ,  Navnath Dnyanoba Yadav

IPC: C07F9/6512 ,  A61K31/675

CPC classification number: C07F9/65128 ,  A61K31/675 ,  C07D401/14 ,  C07F9/65583

Abstract: A compound of structural formula (I), wherein R is H or —PO3H or a pharmaceutically acceptable salt form thereof. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur associated disorders, and other disorders mediated by ion channel function.

Abstract translation: 结构式（I）的化合物，其中R是H或-PO 3 H或其药学上可接受的盐形式。 该化合物可用作钾通道功能的抑制剂和用于治疗和预防心律失常，IKur相关疾病以及由离子通道功能介导的其它病症。